In February, Roche paid US$1.9 billion to acquire Flatiron Health, a 6-year old health technology company that is working to transform oncology electronic health records into regulatory-grade real-world data. For Flatiron CSO and CMO Amy Abernethy — an oncologist and palliative care specialist by training who popularized the term 'financial toxicity' for expensive cancer drugs — this approach is already starting to streamline drug development and clinical trials in ways that are making waves across the health-care industry. Most notably, Flatiron's data set helped to speed up the reimbursement of Roche's ALK inhibitor alectinib by a year and a half. Abernethy spoke with Asher Mullard about how cleaned up and curated real-world data stand to transform clinical trials, drug regulation, competition in the health-care market and even drug prices.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Amy Abernethy. Nat Rev Drug Discov 17, 462–464 (2018). https://doi.org/10.1038/nrd.2018.101
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.101